tbuckley/cabot-search huggingface dataset:
Atopic dermatitis: pathogenesis and therapeutic intervention
Authors: Chengcheng Yue, Hong Zhou, Xiaoyan Wang, Jiadong Yu, Yawen Hu, Pei Zhou, Fulei Zhao, Fanlian Zeng, Guolin Li, Ya Li, Yuting Feng, Xiaochi Sun, Shishi Huang, Mingxiang He, Wenling Wu, Nongyu Huang, Jiong Li
Journal: MedComm (2024)

Abstract The skin serves as the first protective barrier for nonspecific immunity and encompasses a vast network of skin‐associated immune cells. Atopic dermatitis (AD) is a prevalent inflammatory skin disease that affects individuals of all ages and races, with a complex pathogenesis intricately linked to genetic, environmental factors, skin barrier dysfunction as well as immune dysfunction. Individuals diagnosed with AD frequently exhibit genetic predispositions, characterized by mutations that impact the structural integrity of the skin barrier. This barrier dysfunction leads to the release of alarmins, activating the type 2 immune pathway and recruiting various immune cells to the skin, where they coordinate cutaneous immune responses. In this review, we summarize experimental models of AD and provide an overview of its pathogenesis and the therapeutic interventions. We focus on elucidating the intricate interplay between the immune system of the skin and the complex regulatory mechanisms, as well as commonly used treatments for AD, aiming to systematically understand the cellular and molecular crosstalk in AD‐affected skin. Our overarching objective is to provide novel insights and inform potential clinical interventions to reduce the incidence and impact of AD.
788P Analyses of long-term safety and blood levels of daratumumab in patients with multiple myeloma after switching from intravenous to subcutaneous administration
Authors: K. Yamaoka, K. Irie, N. Hiramoto, M. Kume, M. Hirabatake, H. Ikesue, T. Hashida, T. Shimizu, N. Muroi
Journal: Annals of Oncology (2024)
782P The prognostic significance of CD25 &amp; CD123 expression in acute myeloid leukemia
Authors: F.T. Thasneem, G. Narayanan, S.G. Nair, P.N. Purushothaman, S.M. Thambi, A.V. Jayasudha, J. Krishna Km
Journal: Annals of Oncology (2024)
692P Landscape of co-occurring OncoKB tier 1/2 alterations in EGFR-mutated lung adenocarcinoma (LUAD) harboring common driver alterations using circulating tumor DNA (ctDNA) next generation sequencing (NGS) in Asia and the Middle East (AME)
Authors: S. Dawood, C-M. Tsai, B.C. Cho, M-J. Ahn, N. Peled, S.M. Lim, N. Sandhir, S. Olsen
Journal: Annals of Oncology (2024)
717P Non-SqCC EGFR-mutant NSCLC patients with RAS-PI3K-AKT-RAF alterations have poorer response to EGFR-TKIs and overall survival
Authors: Y-C. Hsiao, P-H. Lee, Y-H. Huang, K-H. Hsu, J-S. Tseng, G-C. Chang, T-Y. Yang
Journal: Annals of Oncology (2024)
773P Utility of the Kyoto Prognostic Index in lower-risk DLBCL: A supplementary analysis of JCOG0601
Authors: T. Kobayashi, K. Ohmachi, T. Kinoshita, R. Machida, N. Nakamura, J. Kuroda, K. Ohshima, K. Ando, W. Munakata, H. Nagai
Journal: Annals of Oncology (2024)
657P Landscape of KRAS mutations in non-small cell lung cancer (NSCLC) patients from Asia and Middle East (AME) using circulating tumor DNA (ctDNA)
Authors: A. Rauthan, V. Noronha, R. Bharat, S.S. Jain, S. Olsen, N. Joshi, K. Prabhash
Journal: Annals of Oncology (2024)
774P High MTV and low CD4/CD8 ratio before apheresis are poor prognostic factors in patients with r/r LBCL treated with CAR T-cell therapy
Authors: M. Mino, Y. Yagi, K. Yusuke, Y. Sasaki, A. Takahara, T. Tamura, S. Nakamura, T. Okuya, S. Matsuda, T. Shimizuguchi, N. Shingai, S. Kurosawa, T. Toya, H. Shimizu, Y. Najima, K. Haraguchi, N. Doki, Y. Okuyama, M. Suzuki, T. Shimoyama
Journal: Annals of Oncology (2024)
684P A phase I study of a common neoantigen srRNA vaccine (JCXH-212) with or without toripalimab in patients with non-small cell lung cancer(NSCLC)
Authors: M. Zhuo, H. Chen, Y. Liu, X. Guo, Z. Wang, B. Jia, J. Wang, N.T. Le, J. Fu, Y. Lin, F. Huang, M. Wang, H. Wu, Z. Guo
Journal: Annals of Oncology (2024)
704P Exploring the optimal tumour mutational burden (TMB) cutoff for predicting efficacy of immune checkpoint inhibitors (ICI) in Chinese patients with advanced non-small-cell lung cancer (NSCLC): A territory-wide study
Authors: V.H.F. Lee, C.H.L. Wong, M.K.L. Chiu, E.Y-L. Ko, K.M. Cheung, S.F. Nyaw, T.Y. Kam, M.Y. Lim, S.T.F. Mok, C.K. Kwan, A.W.M. Lee, A. El-Helali
Journal: Annals of Oncology (2024)
710P Retrospective study on the tolerability of anti-PD-L1 antibody plus platinum-etoposide for elderly patients with extensive-stage small-cell lung cancer based on body mass index
Authors: Y. Terashima, S. Takeuchi, T. Inoue, K. Miyadera, T. Tozuka, S. Kitagawa, A. Fukuizumi, K. Hisakane, N. Onda, A. Miyanaga, K. Kasahara, M. Seike
Journal: Annals of Oncology (2024)
772P Comparative analysis of myelodysplastic syndrome (MDS) and clonal cytopenia of undetermined significance (CCUS) using a genetic approach
Authors: Y. Kang, S. Shin, Y.J. Choi, S-T. Lee, J.R. Choi, H.W. Kook, H. Cho, H. Chung, J.E. Jang, D.Y. Hwang, J.S. Kim, J-W. Cheong
Journal: Annals of Oncology (2024)
614MO A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)
Authors: L. Zhang, W.F. Fang, S. Zhao, Y. Yu, T.X. Yong, X. Dong, W. Zhuang, Y. Hu, F. Luo, Q. Wang, Q. Chu, Z. Fu, Y. Yao, X. Ma, C. Ding, J. Hao, X. Yang, X. Wan, M. Li, Y. Yang
Journal: Annals of Oncology (2024)
640P Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation
Authors: B.C. Cho, Y. Shen, Z. Li, S. Lu, M.A. Lee, Z. Song, J.J.W. Park, S.M. Lim, J. Zhao, G. Richardson, Y. Zhang, J. Zhang, A. Liu, C. Chen, Y. Liu, H. Rui, J.Q. Chen, A.H. Wang, J. Zhang, T.S.K. Mok
Journal: Annals of Oncology (2024)
605P Performance of AI-based software for pulmonary nodule detection and characterization on chest X-ray and correlation with CT findings: A retrospective study
Authors: R. Ravind, S. Chattoraj, S. Shivabasappa, A. Singh, R. Chamadia, S. Sathyamurthy, D. Robert, J. Jeeson, N.S. Vanpully, S.M.J. Shaikh, R. Bose K, M. Nasery
Journal: Annals of Oncology (2024)
771P Systematic review of chemotherapy followed by reduced dose radiotherapy regimens for primary central Nervous system Germ cell tumor
Authors: F. Dharmaraja, F. Wijovi, A. Tancherla, V. Angelica, K. Wibowo, C.L. Budiputri, E.F. Trimillenia, A. Kurniawan
Journal: Annals of Oncology (2024)
785P Cytogenetic and clinical profile of CML patients presenting in blast crisis: Prospective study from a regional cancer centre in South India
Authors: K.G. Asutkar, S.C. Saldanha, S. Ali, L.A. Jacob, S. Babu Mc, K.N. Lokesh, A.H. Rudresha, R.K. Lakkavalli Krishnappa, S. Siddappa, V.B. Maleyur
Journal: Annals of Oncology (2024)
666P First-line camrelizumab plus chemotherapy for brain metastases in NSCLC: The CTONG 2003 randomized controlled trial
Authors: J-J. Yang, Y. Li, Q. Yu, Q. Bu, L. Lin, F. Ning, G. Wu, G. Lin, A. Zang, S. Ma, C. Zhou, A. Liu, Y. Zhao, C. Wang, Y. Yao, G. Han, J. Zhao, Y. Pan, J. Lv, Y-L. Wu
Journal: Annals of Oncology (2024)
LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis
Authors: P. Grivas, T.B. Powles, C. Vulsteke, M. Gross Goupil, S.H. Park, A. Necchi, M. De Santis, I. Duran, R. Morales Barrera, J. Guo, C.N. Sternberg, J. Bellmunt, P.J. Goebell, F. Boateng, M. Sierecki, L. Wang, C. Sima, J. Waldes, S.T. Tagawa, Y. Loriot
Journal: Annals of Oncology (2024)
645P The Impact of driver gene alteration type on the efficacy of immune checkpoint inhibitors
Authors: H. Tsuruoka, A. Mouri, T. Shukuya, T. Tsuda, Y. Nagai, H. Ashinuma, S. Kataoka, H. Tanaka, S. Takahashi, Y. Yamanaka, S. Soda, T. Shoji, S. Watanabe, Y. Tsukita, Y. Tamura, K. Hayashihara, S. Morita, K. Kobayashi, M. Maemondo
Journal: Annals of Oncology (2024)
626MO Tarlatamab in previously treated small cell lung cancer (SCLC): Subgroup analysis of patients from the Asia region in the phase II DeLLphi-301 study
Authors: B.C. Cho, K. Ohashi, H. Izumi, J-S. Lee, J-Y. Han, C.L. Chiang, H. Akamatsu, S. Huang, A. Hamidi, S. Mukherjee, K.L. Xu, M-J. Ahn
Journal: Annals of Oncology (2024)
615P Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stg III EGFR-mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): Final analysis of a global real-world (rw) study
Authors: M-J. Ahn, S.H. Lin, C-T. Yang, J.B. Lee, J. Neal, K. Okishio, K. Nishino, D. Smith, M. Rauter, M. Jimenez, S.P. Nagar, F. Nasirova, Y.J. Kim
Journal: Annals of Oncology (2024)
656P Real-World (RW) frontline (1L) treatments (Txs) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EFGR) exon 20 insertions (exon20ins) and adjusted comparisons versus PAPILLON study
Authors: C. Chouaid, L. Bosquet, C. Knott, Z. Li, M. Schaeffer, X. Lin, C. Schioppa, N. Perualila, J. Diels, E. Quintero, F. Galea, A. Hulten, A. Greystoke
Journal: Annals of Oncology (2024)
621P Comparison of biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation in elderly and younger patients
Authors: Y. Nunomura, H. Tanaka, T. Shimanaka, S. Oyama, T. Miura, H. Odagiri, Y. Kobori, M. Ishidoya, K. Chubachi, T. Akita, T. Shiratori, H. Sakamoto, Y. Ishioka, T. Makiguchi, K. Taima, T. Morimoto, D. Miura, Y. Hasegawa, T. Sadatomo
Journal: Annals of Oncology (2024)
642P Phase II trial of lazertinib plus pemetrexed/carboplatin in patients with EGFR-mutant recurrent or metastatic non-small cell lung cancer who failed prior lazertinib (LUCAS): Interim analysis
Authors: M.H. Hong, Y.S. Kim, H. Ahn, S. Lee, Y. Lee, B-C. Ahn, M-J. Ahn, J.S. Ahn, S. Park, S-H. Hong, B.Y. Shim, K.H. Lee, C.G. Kim, H.R. Kim
Journal: Annals of Oncology (2024)
637P Taletrectinib vs repotrectinib in ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)
Authors: M. Nagasaka, G. Liu, N. Pennell, Y. Ohe, M. Pérol, S. Li, M. Chen, L. Bazhenova, C. Zhou
Journal: Annals of Oncology (2024)
759P Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Authors: C. Li, D. Zhu, Z. Fan, Y. Chen, Y. Chen, Y. Li, M. Ji, P. Duan, J. Su, J. Yang, Y. Tang, M. Zhang, S. Wang, G. Yu, Y. Huang, R. Chen, X. Hu, L. Wang, Q. Wang, J. Li
Journal: Annals of Oncology (2024)
653P Baseline and 3 weeks on-treatment plasma EGFR mutation (EGFRm) dynamics in patients with EGFR mutant advanced NSCLC treated with first-line osimertinib: A prospective, multi-center, real-world analysis
Authors: J. Wang, Z. Wang, J. Zhong, J. Duan, J. Zhao, Z. Wang, M. Zhuo, C. Zhou, Z. Li, X. Yi, J. Chang, S. Jin, D. Wu, Q. Song, X. Dong, Y. Cheng, B. Jin, D. Lv, Z. Liu, L. Wang
Journal: Annals of Oncology (2024)
725TiP Osimertinib combined with bevacizumab and chemotherapy as first-line treatment in EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations
Authors: Y. xiong, Y. Wang, W. Zhang, M. Shen, S. li, X. Zhang, X. Ren, S. Wang, L. Liu
Journal: Annals of Oncology (2024)
620P Pembrolizumab with radiotherapy versus pembrolizumab alone in non-small cell lung cancer: A systematic review and meta-analysis
Authors: K. Wibowo, C.L. Budiputri, A.I. Chandra, A.M.C. Agus, A. Tancherla, F. Dharmaraja, F. Wijovi, V. Angelica, A. Kurniawan
Journal: Annals of Oncology (2024)
634P Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo)
Authors: S.C-H. Kao, M. Reck, S.V. Liu, R. Dziadziuszko, M.J. Hochmair, F. Huemer, J. Gilberto de Castro, R. Bernabe Caro, S.H. Kim, D.M. Kowalski, Z.G. Andric, M. Oancea, M. Kaul, H. Li, B. Danner, M.C. Lee, B.Y. Nabet, S. Sugawara
Journal: Annals of Oncology (2024)
748P Multimodal integration of radiology, pathology and transcriptomics for prediction of response to neoadjuvant therapy in patients with retroperitoneal liposarcoma
Authors: L. Ma, P. Tao, P. Fan, J. Wang, Z. Wang, Y. Hou, Y. Zhou, W. Lu, Y. Zhang, H. Tong
Journal: Annals of Oncology (2024)
652P 3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
Authors: C. Verschraegen, Z.G. Andric, F.V. Moiseenko, T. Makharadze, A. Oleksiienko, E.P. Yanez Ruiz, S.H. Kim, K. Ahn, T.H. Park, H.A. Ju, E.H. Baek, S. Kwon, S.J. Lee, I. Chang, S.H. Kim, H.A. Kim, E. Lee, Y. Ohe
Journal: Annals of Oncology (2024)
651P Efficacy and safety outcomes of Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study): Long-term follow-up analysis
Authors: Y. Yu, J. Zhou, X. Li, K. Goto, X. Min, J. Cui, L. Wu, J. Sakakibara-Konishi, Y. Shu, X. Dong, None L. li, Y. Yoneshima, C. Zhou, X. Li, Y. Zhang, D. Huang, F. Li, M. Qin, M. Li, S. Lu
Journal: Annals of Oncology (2024)
683P Aumolertinib plus anlotinib in advanced EGFR-mutant NSCLC with brain metastasis (Alot BRAIN): A single-arm, phase II study (GASTO 1063) (updated data)
Authors: L.K. Chen, J. Chen, M.C. Li, H. Yu, B.S. Zhang, Y. Pan, X. Hou
Journal: Annals of Oncology (2024)
707P Investigation of prognostic factors in extensive stage small cell lung cancer with immune checkpoint inhibitors in first-line treatment using real-world data: Are immune-related adverse events also a prognostic factor?
Authors: T. Nishimura, H. Fujimoto, T. Fujiwara, K. Ito, A. Fujiwara, H. Yuda, H. Itani, E.C. Gabazza, T. Kobayashi
Journal: Annals of Oncology (2024)
667P Furmonertinib 160mg as first-line treatment for metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases
Authors: Y. Zhang, L. Zeng, N. Yang, W. Jiang, Y. Xiong, Z. Wang, H. Yang, L. Liu, C. Zhou, F. Zeng
Journal: Annals of Oncology (2024)
672P Association between the administration time and therapeutic effect of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study
Authors: Y. Iwahashi, A. Tamiya, T. Tanaka, M. Tamiya, A. Tsukaguchi, Y. Inagaki, Y. Taniguchi, K. Okishio
Journal: Annals of Oncology (2024)
609P Camrelizumab plus platinum doublet chemotherapy as adjuvant treatment of stage IIA-IIIA non-small cell lung cancer: A phase II, single-arm research
Authors: H. Xu, X. Kong, S. Zhao, K. Zhu, B. Shi, Y. Wang, B. Ni, B. Han, J. Hou, J. Bu, Y. Gu, F. Ren, S. Xu
Journal: Annals of Oncology (2024)
689P Patterns of disease progression and efficacy of local ablative therapy among patients with metastatic EGFR-mutation positive non-small cell lung cancer treated with first-line osimertinib
Authors: C.C.A. Chen, O.H. Chen, K. Mok, K.C. Lam, W.C.K. Lee, S.T.F. Mok, T.Y.J. Ng, D. Johnson, L.L. Chan, K.C.K. Yan, W. Wong, B. Lam, M.P. Lee, T.S.K. Mok, S.C.M. Li
Journal: Annals of Oncology (2024)
616P Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): Post-progression outcomes from the phase III LAURA study
Authors: M. Ozguroglu, M-J. Ahn, X. Dong, J.C-H. Yang, S. Oizumi, K. Goto, M. Cobo Dols, S-W. Kim, T-C. Hsia, J. Chindaprasirt, F.K. Fujiki, N. Valdiviezo, L. Poole, A.L. Evans, E. Armenteros Monterroso, S. Lu
Journal: Annals of Oncology (2024)
685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China
Authors: Y-K. Shi, D. Lv, W. Feng, S. Liu, P. Xing, Y. Yu, J. Yin, X. Ren, J. Zhang, G. Han, Y. Zhang, S. Cang, J. Chen, E. Chen, L. Meng, Y. Zhang
Journal: Annals of Oncology (2024)
687P Profile of actionable oncogenic alterations (AGA) among patients with advanced NSCLC in South India: A multicentric study
Authors: K. Pavithran, N. Warrier, A. Philip, K.S. Udupa, A.R. Warrier, G. Kormath Veetil, S.L. Cyriac, B. Rangarajan, J. Mathews, K. Prasad, W.M. Jose, N.K. Haridas, R.M. P, S. Cyriac, A. Joy, A.S. Komaranchath, A. Pai, S. Mailankody, M. Rangasamy
Journal: Annals of Oncology (2024)
627MO POD1UM-304: Phase III study of retifanlimab plus platinum-based chemotherapy (Chemo) as first-line (1L) therapy for nonsquamous or squamous metastatic non–small cell lung cancer (mNSCLC)
Authors: S. Lu, O. Vynnychenko, Y. Kulyaba, V. Kuchava, A. Ibrahim, F.V. Moiseenko, C. Arslan, D.T. Nguyen, M. Zhang, M.D. Petrovic, I. Cicin, K. Bibichadze, T. Cil, M. Cornfeld, C. Tian, M. Munteanu, C.V.D.M. Sette, I. Bondarenko
Journal: Annals of Oncology (2024)
643P Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE
Authors: A. Mouri, T. Tsuda, M. Oki, E. Ichihara, H. Tanaka, K. Azuma, R. Arai, S. Kuyama, H. Akamatsu, K. Otsubo, H. Ajimizu, M. Matsumoto, Y. Seto, K. Uchibori, H. Hayashi, E. Miyauchi, N. Ishizuka, Y. Kajihara, Y. Nakagawa, R. Katayama
Journal: Annals of Oncology (2024)
720P Interleukin gene expression and their impact on prognosis in metastatic NSCLC
Authors: S. Meedimale, S.S. Panda, L. Moharana, L. Samantaray, S. Mohanty, D. Dubey, G.K. Purohit, G. Biswas, Y.S. Kumar, A. Sanyal, A. Tiwari, S. Harankhedkar, A. Dubey, R. Singhal, S.K. Swain, P.R. Sahoo, A. Bhange, I. Bhavya, S.S. Mohanty
Journal: Annals of Oncology (2024)
750P Clinicopathological features and treatment outcomes of adolescents and adults Rhabdomyosarcoma: A single institutional experience
Authors: R. Joarder, P.G. Bhargava, S. Rath, A. Mehta, S. Srinivas, A. Gulia, M. Pruthi, P. Nayak, A. Janu, N. Chakrabarty, M. Ramadwar, B. Rekhi, A. Puri, J. Bajpai, V. Noronha, K. Prabhash
Journal: Annals of Oncology (2024)
682P First-line serplulimab for advanced squamous non-small cell lung cancer: A multicenter, single-arm, real-world ASTRUM-004R study
Authors: B. Shen, Z. Yu, H. Ding, H. Wang, J. Li, X. Xu, G. Tian, G. Han, L. Yin, Y. Ji, Z. Zhou, L. Zhou, X. Zhang, C. Sun, N. Ding
Journal: Annals of Oncology (2024)
661P Prospective multi-institutional observational study of anti-PD-1/PD-L1 antibody (anti-PD-1/anti-PD-L1) re-treatment in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-1/PD-L1 plus chemotherapy: NJLCG1901
Authors: H. Tanaka, Y. Kawashima, S. Saito, N. Yoshimura, Y. Tsukita, R. Saito, T. Nakagawa, M. Inomata, H. Nagashima, S. Sugawara
Journal: Annals of Oncology (2024)
711P Prognostic impact of oligometastasis in elderly patients with extensive-stage small cell lung cancer
Authors: D. Morinaga, K. Hashimoto, H. Asahina, H. Tanaka, H. Kikuchi, H. Yokouchi, T. Harada, O. Honjo, R. Shigaki, T. Takashina, Y. Fujita, M. Takahashi, Y. Kawai, R. Kida, K. Ito, N. Sukoh, A. Takahashi, S. Konno, Y. Hosomi, S. Oizumi
Journal: Annals of Oncology (2024)
718P EML4-ALK gene variants and PD-L1 expression: Their Impact on clinical outcomes in ALK-positive NSCLC
Authors: S. Meedimale, L. Moharana, S. Mohanty, L. Samantaray, Y.S. Kumar, A. Sanyal, A. Tiwari, G. Biswas, S.S. Panda
Journal: Annals of Oncology (2024)
721TiP A phase I/II study of davutamig (REGN5093), a MET×MET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update
Authors: M-J. Ahn, B.C. Cho, T.M. Kim, J-Y. Han, C. Kim, B. Shim, A. Drilon, G. Blumenschein, L. Villaruz, J.E. Gray, J-L. Pujol, H. Lena, D. Moro-Sibilot, J. Perez, D.A. Modi, J.S. Park, S. Patel, S. Li, E. Kim, H. Magnan
Journal: Annals of Oncology (2024)
767P A prospective study for assessment of neurocognitive function in patients with grade 2 and 3 gliomas
Authors: A. Mehta, S. Goyal, R. Madan, S. Gy, R. Singh, S. Mohindra, A. Prabhakar, K. Sony, B. Padhi, S. Ghoshal
Journal: Annals of Oncology (2024)
582P Knowledge, attitude and practices of physicians in Pakistan towards onco-hypertension
Authors: M. Hashmi, S.S. Yaqub, U.A.A. Rehman, E.S.A. Alfadul, H.S. Jabeen, M.N.S. Saddique, K.J. Javaid, M.S. Siddique, M.A. Khokhar
Journal: Annals of Oncology (2024)
735P Integrating a data curation artificial intelligence system to identify cancer registry data elements from unstructured electronic health records
Authors: Y-H. Yang, H-J. Dai, J-H. Tsai, Y-C. Chang, T-Y. Wang, C-R. Ke, S-J. Yu, Y-H. Liu, C-J. Huang, C-J. Lee, Y-H. Lee, J-R. Liang, W-M. Fu, S-C. Liao, S-J. Kuo, C-Y. Huang, L-J. Lin, C-C. Wu, G-C. Chang, I-W. Chong
Journal: Annals of Oncology (2024)
690P Clinical outcomes of patients with advanced EGFR mutation positive (EGFRm) non-small cell lung cancer (NSCLC) with MET amplification (METamp) after osimertinib resistance: A multicentre retrospective study
Authors: O.H. Chen, T.Y. Kam, Q. Du, S.F. Nyaw, Y.K. Chik, A.H. Cheung, C. Chow, L.L. Chan, K.C.K. Yan, K. Mok, W. Wong, G. Tsui, C.C.A. Chen, T.S.K. Mok, S.C.M. Li
Journal: Annals of Oncology (2024)
728TiP Osimertinib with chemotherapy as first-line therapy for patients with locally advanced or metastatic epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC): A prospective, multi-centre, real-world study (FOREFRONT)
Authors: B. Han, Q. Wang, B. Zhang, D. Lv, W. Yao, Y. Yu, M. Zhuo
Journal: Annals of Oncology (2024)
644P Tifcemalimab combined with toripalimab and docetaxel as 2nd line treatment for immunotherapy-treated squamous cell non-small cell lung cancer (Sq-NSCLC) patients: A phase Ib/II study
Authors: D. Lv, Y. Zhang, Z. He, Y. Yu, L. Wu, M. Zhao, Y. Yu, W. Zhang, M. Zhang, A. Liu, J. Shi, Y. Chen, C. Wang, H. Zhu, D. Huang, Y. Li, D. Li, J. Gao, S. Lu
Journal: Annals of Oncology (2024)
719P Genomic profiling of driver gene alterations in patients with non-small cell lung cancer, patterns of treatment and impact on survival outcomes: A single center experience of more than 1200 patients
Authors: M.J. Shah, V. Noronha, V.M. Patil, A.C. Singh, N.S. Menon, S. Goud, S. Shah, S. More, A. Kapoor, B. Mishra, P. Chandrani, A. Chougule, O. Shetty, T. Pai, R.K. Kaushal, M. Basu, A. Janu, N. Purandare, K. Maske, K. Prabhash
Journal: Annals of Oncology (2024)
670P Phase III study of zipalertinib plus first-line (1L) platinum-based chemotherapy in patients (pts) with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations (REZILIENT3): Safety lead-in results
Authors: T. Kurata, Y. Fujiwara, K. Naoki, S. Viteri, T. Inoue, N. Hangai, L. Wei, R. Kawabata, V. Wacheck, M. Nishio
Journal: Annals of Oncology (2024)
722TiP Efficacy and safety of combination therapy of sintilimab and chemotherapy with cryoablation in the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC)
Authors: Z. Gao, J. Teng, J. Qian, M. Ma, R. Qiao, J. Lu, F. Pan, H. Zhong
Journal: Annals of Oncology (2024)
709P The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%
Authors: Y. Toyota, T. Hata, T. Yamada, Y. Goto, T. Kijima, S. Watanabe, N. Furuya, T. Oba, T. Ikoma, A. Nakao, K. Tanimura, H. Taniguchi, A. Yoshimura, T. Fukui, D. Murata, K. Kaira, S. Shiotsu, M. Hibino, A. Okada, K. Takayama
Journal: Annals of Oncology (2024)
691P Mechanisms of acquired resistance to first-line (1L) osimertinib in EGFR-mutated (EGFRm) advanced NSCLC: Results from a prospective, multi-center, real-world study in China (FLOURISH study)
Authors: J. Zhou, L. Shen, D. Lv, K. Tang, D. Zhu, Y. Zhao, K. Wang, Y. Wang, L. Xing, J. Cui, L. Ding, X. Shi, J. Zheng, J. Zhou
Journal: Annals of Oncology (2024)
571P The economic sequelae of immune related adverse events secondary to immune checkpoints inhibitors in Qatar: A hospital-perspective analysis
Authors: N.E. Omar, L.K. Shafei, H. Elewa, M.O. Saad, M. Sir Elkhatim, A.R. Alnajjar, A. Gulied, A. Sahal, A. Alasmar, F.E. Gebril, H.M. Afifi, S.M. Nasser, M. Benkhadra, R. Dawoud, S. Elazzazy, A. Hamad
Journal: Annals of Oncology (2024)